Interventional, Open-label, Multiple-dose Study to Investigate the Effects of Multiple Doses of Lu AF35700 on the Pharmacokinetics of Cytochrome P450 (CYP450) Substrates Dextromethorphan (CYP2D6), Caffeine (CYP1A2), Omeprazole (CYP2C19), and Midazolam (CYP3A4/5) in Healthy Young Adults
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2018
At a glance
- Drugs LU AF-35700 (Primary) ; Midazolam
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 05 Jan 2018 Status changed from recruiting to completed.
- 08 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 08 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.